Obesity

Lilly’s Orforglipron Pill Hits Phase 3 Goals, Clearing Path to Global Filings

The small‑molecule, no‑restriction GLP‑1 pill presents a scalable alternative to injectables as regulators weigh its efficacy versus rivals.